These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26011141)

  • 1. Relative bioavailability of orally administered fosphenytoin sodium injection compared with phenytoin sodium injection in healthy volunteers.
    Kaucher KA; Acquisto NM; Rao GG; Kaufman DC; Huntress JD; Forrest A; Haas CE
    Pharmacotherapy; 2015 May; 35(5):482-8. PubMed ID: 26011141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.
    Doak KK; Haas CE; Dunnigan KJ; Reiss RA; Reiser JR; Huntress J; Altavela JL
    Pharmacotherapy; 1998; 18(3):637-45. PubMed ID: 9620116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fosphenytoin: pharmacokinetics and tolerance of intramuscular loading doses.
    Pryor FM; Gidal B; Ramsay RE; DeToledo J; Morgan RO
    Epilepsia; 2001 Feb; 42(2):245-50. PubMed ID: 11240597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenytoin penetration into brain after administration of phenytoin or fosphenytoin.
    Walton NY; Uthman BM; El Yafi K; Kim JM; Treiman DM
    Epilepsia; 1999 Feb; 40(2):153-6. PubMed ID: 9952260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption characteristics of three phenytoin sodium products after administration of oral loading doses.
    Goff DA; Spunt AL; Jung D; Bellur SN; Fischer JH
    Clin Pharm; 1984; 3(6):634-8. PubMed ID: 6509876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
    Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
    Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of IV fosphenytoin pharmacokinetics to determine the loading dose for a clinical trial of canine status epilepticus.
    Coles LD; Leppik IE; Patterson EE; Rivers Z; Mishra U; Cloyd JC
    Epilepsia; 2015 Jun; 56(6):888-94. PubMed ID: 25952988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers.
    Inoue Y; Usui N; Hiroki T; Shimizu K; Kobayashi S; Shimasaki S
    Eur J Drug Metab Pharmacokinet; 2013 Jun; 38(2):139-48. PubMed ID: 22968854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of lacosamide versus fosphenytoin for nonconvulsive seizures.
    Husain AM; Lee JW; Kolls BJ; Hirsch LJ; Halford JJ; Gupta PK; Minazad Y; Jones JM; LaRoche SM; Herman ST; Swisher CB; Sinha SR; Palade A; Dombrowski KE; Gallentine WB; Hahn CD; Gerard EE; Bhapkar M; Lokhnygina Y; Westover MB;
    Ann Neurol; 2018 Jun; 83(6):1174-1185. PubMed ID: 29733464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats.
    Burstein AH; Cox DS; Mistry B; Eddington ND
    Epilepsy Res; 1999 Apr; 34(2-3):129-33. PubMed ID: 10210027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
    Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients.
    Boucher BA; Feler CA; Dean JC; Michie DD; Tipton BK; Smith KR; Kramer RE; Young B; Parks BR; Kugler AR
    Pharmacotherapy; 1996; 16(4):638-45. PubMed ID: 8840370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of phenytoin following intravenous and intramuscular administration of fosphenytoin and phenytoin sodium in the rabbit.
    Muchohi SN; Kokwaro GO; Maitho TE; Munenge RW; Watkins WM; Edwards G
    Eur J Drug Metab Pharmacokinet; 2002; 27(2):83-9. PubMed ID: 12064376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
    Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M
    Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of salivary drug monitoring for detecting efflux transporter overexpression.
    Fagiolino P; Vázquez M; Maldonado C; Ruiz ME; Volonté MG; Orozco-Suárez S; Lazarowski A
    Curr Pharm Des; 2013; 19(38):6701-8. PubMed ID: 23530513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study.
    Di Girolamo G; Keller GA; de Los Santos AR; Schere D; Gonzalez CD
    Clin Ther; 2008 Nov; 30(11):2015-23. PubMed ID: 19108789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of pharmacokinetics and safety between CE-fosphenytoin sodium, fosphenytoin sodium, and phenytoin sodium after intravenous and intramuscular administration in healthy volunteers.
    Li X; Wu M; Sun J; Jin W; Han L; Xu J; Liu J; Zhang H; Wang J; Wang D; Zhang H; Zhang Q; Liu N; Ding Y
    Front Pharmacol; 2023; 14():1204075. PubMed ID: 38044946
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.